SeptRx is developing the SeptRx Intrapocket PFO Occluder (IPO), a platform for percutaneous transcatheter closure of patent foramen ovale. The IPO completed an 11-patient first-in-human trial that the company reports showed 100% closure and 100% safety out to three years. SeptRx plans a larger European trial, InterSEPT, with sites in Frankfurt, Germany and Massy, France; data from that study will be used to apply for CE marking. The company says its recent Series A funding is intended to carry it through CE mark registration and position it for initial commercialization efforts in Europe. SeptRx emphasizes the potential clinical impact given that PFO is present in about 25% of the population and is implicated in cryptogenic stroke, chronic migraine, decompression sickness, and obstructive sleep apnea. The IPO is not approved for sale in any regulatory jurisdiction and is not available for investigational use or commercial sale in the U.S.

Total raised

$3M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2011